Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Chauhan, Bhupendrasinh F ^a   Ben Salah, Raja ^a   Ducharme, Francine M ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ACETIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ASTHMA; CHILD; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; DRUG COMBINATION; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); METHODOLOGY;

ACETATES; ADOLESCENT; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899470721     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009585.pub2     Document Type: Review

References (138)

1. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al.Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. New England Journal of Medicine 2010;362(11):975-85.
2. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, et al.Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. Journal of Pediatrics 2001;138(5):694-8.
3. Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulmonary Pharmacology and Therapeutics 2007;20(6):691-700.
4. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology 2008;121(2):383-9.
5. Strauch E, Moske O, Thoma S, Storm Van's Gravesande K, Ihorst G, Brandis M, et al.A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatric Research 2003;54(2):198-203.
6. Abadoglu O, Mungan D, Aksu O, Erekul S, Misirligil Z. The effect of montelukast on eosinophil apoptosis: induced sputum findings of patients with mild persistent asthma. Allergologia et Immunopathologia 2005;33(2):105-11.
7. Abdel-wahab M, Naiem AA, El-Batch M. Steroid sparing using safer drugs in the management of children and adolescents with chronic asthma. New Horizons in Allergy, Asthma & Immunology. 2009:137-44.
8. American Lung Association Asthma Clinical Research Centers (ALAACRC), Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, et al.Randomized comparison of strategies for reducing treatment in mild persistent asthma. New England Journal of Medicine 2007;356(20):2027-39.
9. Allen-Ramey FC, Duong PT, Goodman DC, Sajjan SG, Nelsen LM, Santanello NC, et al.Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data. Allergy and Asthma Proceedings 2003;24(1):43-51.
10. Anonymous. Steroids better than montelukast in acute asthma exacerbations in children. Journal of the National Medical Association 2010;102(3):259.
11. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, et al.Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. Journal of Allergy and Clinical Immunology 2008;122(6):1127-35.
12. Beak H. The pathobiologic effect of montelukast and inhaled budesonide on exercise-induced bronchoconstriction in children. Journal of Allergy and Clinical Immunology 2011;127(2 Suppl 1):AB83.
13. Barnes ML, Menzies D, Fardon TC, Burns P, Wilson AM, Lipworth BJ. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007;62(1):73-80.
14. Barnes N, Laviolette M, Allen D, Flood-Page P, Hargreave F, Corris P, et al.Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control. Respiratory Medicine 2007;101(8):1652-8.
15. Basu K, Donald HP, Lipworth BJ, Tavendale R, Macgregor DF, Ogston SA, et al.Better asthma control with montelukast than salmeterol in arg-16homozygous children with asthma. Thorax 2010;65(Suppl 4):P181.
16. Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, et al.Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Annals of Allergy, Asthma & Immunology 2006;96(6):800-7.
17. Benitez HH, Arvizu VM, Gutiérrez DJ, Fogelbach GA, Castellanos Olivares A, Vázquez Nava F, et al.Nasal budesonide plus zafirlukast vs nasal budesonide plus loratadine-pseudoephedrine for controlling the symptoms of rhinitis and asthma. Revista Alergia Mexico 2005;52(2):90-5.
18. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, et al.Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Respiratory Medicine 2000;94(6):612-21.
19. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, et al.Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891.
20. Bleecker ER, Welch MJ, Weinstein SE, Kalberg C, Johnson M, Edwards L, et al.Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. Journal of Allergy and Clinical Immunology 2000;105(6):1123-9.
21. Bousquet J, Menten J, Tozzi CA, Polos PG. Oral montelukast sodium versus inhaled fluticasone propionate in adults with mild persistent asthma. Journal of Applied Research 2005;5(3):402-14.
22. Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. Journal of Asthma 2012;49(5):530-4.
23. Buchvald FF, Bisgaard H. Comparison of add-on of leukotriene receptor antagonist vs long-acting beta 2-agonist of FeNO in asthmatic children on regular inhaled budesonide. European Respiratory Journal 2002;20(Supp 38):431s.
24. Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Annals of Allergy, Asthma & Immunology 2003;91(3):309-13.
25. Bukstein DA, Luskin AT, Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Annals of Allergy, Asthma & Immunology 2003;90(5):543-9.
26. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. Journal of Allergy and Clinical Immunology 1999;103(6):1075-80.
27. Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S, et al.Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. Journal of Allergy and Clinical Immunology 2001;107(3):461-8.
28. Caffey LF, Raissy HH, Marshik P, Kelly HW. A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma. Pediatric Asthma, Allergy & Immunology 2005;18(3):123-30.
29. Cakmak G, Demir T, Gemicioglu B, Aydemir A, Serdaroglu E, Donma O. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients. Tohoku Journal of Experimental Medicine 2004;204(4):249-56.
30. Costa-Katz CL, Livnat G, Hakim F, Vilozni D, Bentur Y, Bentur L. The effect of beclomethasone dipropionate in ultrafine particles on bronchial hyper-reactivity in young children. Acta Paediatrica 2012 Jan 27 [Epub ahead of print]; Vol. 101, issue 5:e219-24.
31. Currie GP, Lee DK, Dempsey OJ, Fowler SJ, Cowan LM, Lipworth BJ. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. British Journal of Clinical Pharmacology 2003;55(6):609-15.
32. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. American Journal of Respiratory and Critical Care Medicine 2003;167(9):1232-9.
33. Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clinical Therapeutics 2004;26(11):1895-1904.
34. Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122(1):151-9.
35. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. Journal of Allergy and Clinical Immunology 2002;109(1):68-74.
36. Deschildre A, Béghin L, Salleron J, Iliescu C, Thumerelle C, Santos C, et al.Home telemonitoring (forced expiratory volume in 1 s) in children with severe asthma does not reduce exacerbations. European Respiratory Journal 2012;39(2):290-6.
37. Djukanović R, Wilson SJ, Moore WC, Koenig SM, Laviolette M, Bleecker ER, et al.Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respiratory Medicine 2010;104(10):1425-35.
38. Duong M, Amin R, Baatjes AJ, Kritzinger F, Qi Y, Meghji Z, et al.The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction. Journal of Allergy and Clinical Immunology 2012 Apr 24 [Epub ahead of print]; Vol. 130, issue 2:535-539.e3.
39. Eakin MN, Rand CS, Bilderback A, Bollinger ME, Butz A, Kandasamy V, et al.Asthma in Head Start children: effects of the Breathmobile program and family communication on asthma outcomes. Journal of Allergy and Clinical Immunology 2012;129(3):664-70.
40. Farber I, Geppe N, Putyato T. Efficacy of leukotriene receptors modifiers (LRM) and inhaled glucocorticoids (ICS) in the treatment of children with bronchial asthma (BA) and allergic rhinitis (AR). Allergy 2010;65(s92):1858.
41. Finn AF, Bonuccelli CM, Traxler BM, Beatty SE. Zafirlukast improves asthma control in children treated with and without inhaled corticosteroids. European Respiratory Journal 2000;16(Suppl 31):307.
42. Fogel RB, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S, et al.Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Annals of Allergy, Asthma & Immunology 2010;104(6):511-7.
43. Fritsch M, Uxa S, Horak Jr F, Putschoegl B, Dehlink E, Szepfalusi Z, et al.Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. Pediatric Pulmonology 2006;41(9):855-62.
44. Ghiro L, Zanconato S, Rampon O, Piovan V, Scollo M, Baraldi E. Effect of montelukast added to inhaled steroids on exhaled NO in asthmatic children. European Respiratory Journal 2001;18(33):40s.
45. Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. European Respiratory Journal 2002;20(3):630-4.
46. Igde M, Anlar FY. The efficacy of montelukast monotherapy in moderate persistent asthmatic children. Iranian Journal of Allergy, Asthma, and Immunology 2009;8(3):169-70.
47. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, et al.Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Annals of Allergy, Asthma & Immunology 2004;92(6):641-8.
48. Irvin CG, Kaminsky DA, Anthonisen NR, Castro M, Hanania NA, Holbrook JT, et al.Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. American Journal of Respiratory and Critical Care Medicine 2007;175(3):235-42.
49. Jat GC, Mathew JL, Singh M. Treatment with 400 mug of inhaled budesonide vs 200 mug of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Annals of Allergy, Asthma & Immunology 2006;97(3):397-401.
50. Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, et al.Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. European Respiratory Journal 2005;25(1):41-6.
51. Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centred outcomes with three classes of asthma medication. European Respiratory Journal 2005;26(1):36-44.
52. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, et al.Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Paediatrics 2007;120(3):e702-e712.
53. Jung J, Lee J, Kim J. Treatment of inhaled corticosteroid and leukotriene receptor antagonist in Korean young cough variant asthma children. Journal of Allergy and Clinical Immunology 2006;117:S93.
54. Kamenov S, Kamenov A, Kamenov B. Effect of fluticasone and montelukast in school children with asthma. European Respiratory Journal 2007;30(Suppl 51):459s.
55. Karaman O, Arli O, Uzuner N, Islekel H, Babayigit A, Olmez D, et al.The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children. Allergy and Asthma Proceedings 2007;28(2):204-9.
56. Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, et al.Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Canadian Respiratory Journal 2009;16(Suppl A):17A-31A.
57. Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children. Allergology International 2006;55(3):287-93.
58. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al.Montelukast added to inhaled beclomethasone in treatment of asthma. American Journal of Respiratory and Critical Care Medicine 1999;160(6):1862-8.
59. Lee DKC, Jackson CM, Haggart K, Lipworth BJ. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest 2004;125(4):1372-7.
60. Lipworth BJ, Dempsey OJ, Aziz I, Wilson AM. Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. American Journal of Medicine 2000;109:114-21.
61. Marogna M, Colombo F, Spadolini I, Massolo A, Berra D, Zanon P, et al.Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. Journal of Investigational Allergology & Clinical Immunology 2010;20(2):146-52.
62. Matsuse H, Fukahori S, Tsuchida T, Kawano T, Tomari S, Matsuo N, et al.Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. Journal of Asthma 2012; Vol. 49, issue 6:637-41.
63. Mendes ES, Campos MA, Hurtado A, Wanner A. Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma. American Journal of Respiratory and Critical Care Medicine 2004;169(10):1131-4.
64. Miraglia del Giudice M, Piacentini GL, Capasso M, Capristo C, Maiello N, Boner AL, et al.Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respiratory Medicine 2007;101(8):1809-13.
65. Nathan RA, Bleecker ER, Kalberg C, Fluticasone Propionate Study Group. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. American Journal of Medicine 2001;111(3):195-202.
66. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al.Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. Journal of Allergy and Clinical Immunology 2000;106(6):1088-95.
67. Nelson HS, Weiss ST, Bleecker EK, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
68. Ng DKK, Chan CH, Wu S, Chow PY, Wong LSW, Fu YM, et al.Oral montelukast versus inhaled budesonide in children with mild persistent asthma: a pilot study. The Hong Kong Journal of Paediatrics 2007;12(1):3-10.
69. O'Connor RD, Gilmore AS, Manjunath R, Stanford RH, Legorreta AP, Jhingran PM. Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives. Current Medical Research and Opinion 2006;22(3):453-61.
70. O'Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. American Journal of Respiratory and Critical Care Medicine 2003;167(5):745-50.
71. Ostrom NK, DeCotiis BA, Lincourt WR, Edwards LD, Crim CC. A comparison of low does fluticasone propionate and montelukast in children 6-12 years of age with persistent asthma. American Thoracic Society 99thInternational Conference; 2003 May 16-21; Seattle. 2003; Vol. A117:Poster D79.
72. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, et al.Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. Journal of Pediatrics 2005;147(2):213-20.
73. Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. Journal of Asthma 2009;46(4):413-20.
74. Patel YA, Patel P, Bavadia H, Dave J, Tripathi CB. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma. Journal of Postgraduate Medicine 2010;56(4):270-4.
75. Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, et al.Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatric Pulmonology 2007;42(9):838-43.
76. Peroni D, Bodini A, Miraglia Del Giudice M, Loiacono A, Baraldi E, Boner AL, et al.Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens. Allergy 2005;60(2):206-10.
77. Philip G, Villarán C, Shah SR, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. Journal of Asthma 2011;48(5):495-502.
78. Phipatanakul W, Greene C, Downes SJ, Cronin B, Eller TJ, Schneider LC, et al.Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Annals of Allergy, Asthma & Immunology 2003;91(1):49-54.
79. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al.Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58(3):211-6.
80. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al.Leukotriene antagonists as first-line or add-on asthma-controller therapy. New England Journal of Medicine 2011;364(18):1695-1707.
81. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, et al.Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52(7):45-8.
82. Riccioni G, Vecchia RD, Castronuovo M, Di Ilio C, D'Orazio N. Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent asthma treated with montelukast: a 16-week single-blind randomized study. Annals of Clinical and Laboratory Science 2005;35(3):285-9.
83. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001;357(9273):2007-11.
84. SAM40030. A phase IV, multicentre, randomised, double blind, single dummy, parallel group study to compare the anti-inflammatory action of Seretide 50/100 bd via MDI with Flixotide 100 μg bd via MDI plus montelukast 10mg od for 12 weeks in adults with mild to moderate asthma who are currently taking inhaled corticosteroids but have a requirement for further therapy. www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=SAM40030&studyId=1112A112-B8F4-42A0-BE6C-EF7A1620090F&compound=SAM40030&type=GSK+Study+ID&letterrange=All (accessed 3/9/13).
85. SAS40036. A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS combination product 100/50 mcg BID, fluticasone propionate DISKUS 100 mcg BID, salmeterol xinafoate DISKUS 50 mcg BID, or oral montelukast 10 mg QD. www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=SAS40036&studyId=28A94A00-AEBF-45B7-B75B-D13827C5F6D8&compound=SAS40036&type=GSK+Study+ID&letterrange=All (accessed 3/9/13).
86. SD-004CR-0216. Oxis Turbuhaler® (formoterol), Accolate® (zafirlukast) or placebo as add on treatment to Pulmicort Turbuhaler® (budesonide) in asthmatic patients on inhaled steroids. www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/8611707 (accessed 3/9/13).
87. Shah AR, Sharples LD, Solanki RN, Shah KV. Double-blind, randomised, controlled trial assessing controller medications in asthma. Respiration 2006;73(4):449-56.
88. Sims EJ, Jackson CM, Lipworth BJ. Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype. British Journal of Clinical Pharmacology 2003;56(1):104-11.
89. Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR, et al.The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012; Vol. 67, issue 12:1052-60.
90. Smugar SS, Fogel R, Aristizabal G, Rosario N, Loeys T, Gaile S, et al.Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction. European Respiratory Society Annual Congress 2009; Vol. 212s:P1221.
91. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clinical and Experimental Allergy 2002;32(2):264-9.
92. Stelmach I, Bobrowska-Korzeniowska M, Majak P, Stelmach W, Kuna P. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulmonary Pharmacology & Therapeutics 2005;18(5):374-80.
93. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM, et al.A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine 2004;98(11):1051-62.
94. Tognella S, Micheletto C, Visconti MP, Dal Negro RW. Additive effects of montelukast on bronchial hyperresponsiveness to MCh and LTE4 urine levels in mild-persistent atopic asthmatics assuming ICS. Chest 2004;126(Suppl 4):814S.
95. Tohda Y, Fujimura M, Taniguchi H, Takagi K, Igarashi T, Yasuhara H, et al.Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clinical and Experimental Allergy 2002;32(8):1180-86.
96. Tsuchida T, Matsuse H, Machida I, Kondo Y, Saeki S, Tomari S, et al.Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. Allergy and Asthma Proceedings 2005;26(4):287-91.
97. Ulrik CS, Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Clinical and Experimental Allergy 2010;40(4):576-81.
98. Verini M, Consilvio NP, Di Pillo S, Cingolani A, Spagnuolo C, Rapino D, et al.FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy 2010 May 18 [Epub ahead of print].
99. Virchow JC Jr, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. American Journal of Respiratory and Critical Care Medicine 2000;162(2 Pt 1):578-85.
100. Virnig C, Gern JE. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2008;122:S218-S219.
101. Weiss KB, Gern JE, Johnston NW, Sears MR, Jones CA, Jia G, et al.The back to school asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Annals of Allergy, Asthma & Immunology 2010;105(2):174-81.
102. Williams B, Noonan G, Reiss TF, Knorr B, Guerra J, White R, et al.Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clinical and Experimental Allergy 2001;31(6):845-54.
103. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001;119(4):1021-6.
104. Wilson ECF, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, et al.Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. PharmacoEconomics 2010;28(7):597-608.
105. Yaldiz E, Özkan G, Özdemir A, Gür A, Çamsari G. The role of montelukast in the reduction of high dose inhaled steroid in asthmatic patients. European Respiratory Journal 2000;16(Suppl 31):457s.
106. Yasui H, Fujisawa T, Inui N, Kato M, Hashimoto D, Enomoto N, et al.Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation. Respiratory Medicine 2012;106(4):508-14.
107. Yildirim Z, Ozlu T, Bulbul Y, Bayram H. Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma. Respirology 2004;9(2):243-8.
108. Andersson F, Kjellman M, Forsberg G, Möller C, Arheden L. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. Annals of Allergy, Asthma & Immunology 2001;86(5):537-44.
109. British Thoracic Society, Scottish Intercollegiate Guidelines Network (BTS). British Guideline on the Management of Asthma (revised 2011). http://www.sign.ac.uk/guidelines/fulltext/101/ (accessed 3/9/13).
110. Busse WW, O'Bryne PM, Holgate ST. Asthma pathogenesis. In: Adkinson Jr NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FE editor(s). Middleton's Allergy, Principles & Practice. 6th Edition. Philadelphia: CV Mosby, 2006.
111. Calhoun WJ. Anti-leukotrienes for asthma. Current Opinion in Pharmacology 2001;1:230-4.
112. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009;123(3):e519-e525.
113. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006923.pub2]
114. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010005.pub2]
115. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002314.pub3]
116. de Benedictis FM, Teper A, Green RJ, Boner AL, Williams L, Medley H, International Study Group. Effect of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Archives of Pediatrics & Adolescent Medicine 2001;155(11):1248-54.
117. Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003133.pub2]
118. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-634.
119. Eid E, Morton R, Olds B, Clark P, Sheikh S, Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics 2002;109(2):217-21.
120. Enting D, Schokker S, Duiverman EJ, van der Molen T. The effectiveness of inhaled corticosteroid therapy in preschool children with asthma: a systematic review of literature. Primary Care Respiratory Journal 2003;12(2):52-7.
121. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (updated 2011). www.ginasthma.org/local/uploads/files/GINA_Report2011_May4.pdf (accessed 3/9/13).
122. Heuck C, Heickendorff L, Wolthers OD. A randomized controlled trial of short term growth and collagen turnover in asthmatics with inhaled formoterol and budesonide. Archives of Disease in Childhood 2000;83(4):334-9.
123. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
124. Linzer JF. Review of asthma: pathophysiology and current treatment options. Clinical Pediatric Emergency Medicine 2007;8:87-95.
125. Lougheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, et al.Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for children six years of age and over, and adults. Canadian Respiratory Journal 2012;19(2):127-64.
126. Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, et al.The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of Allergy, Asthma, & Immunology 2005;95(1):66-71.
127. Muijsers RB, Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatric Drugs 2002;4(2):123-39.
128. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (accessed 3/9/13).
129. National Asthma Council Australia. Asthma Management Handbook 2006. www.nationalasthma.org.au/uploads/handbook/370-amh2006_web_5.pdf (accessed 3/9/13).
130. Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and place in therapy. Therapeutic Advances in Chronic Disease 2011;2(1):47-58.
131. Public Health Agency of Canada (PHAC). Life and Breath: Respiratory Disease in Canada. Respiratory Disease in Canada 2007.
132. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2005;172:831-6.
133. Pohunek P, Kuna P, Jorup C, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology 2006;17(6):458-65.
134. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al.An Official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine 2009;180(1):59-99.
135. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
136. Sharek PJ, Bergman D, Ducharme FM. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001282]
137. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. New England Journal of Medicine 2000;343(5):332-6.
138. World Health Organization (WHO). Asthma Fact Sheet No.307. www.who.int/mediacentre/factsheets/fs307/en/index.html (accessed 3/9/13).